ABSTRACT
Liposome research has been a major beneficiary of a recent resurgence of interest in vaccine adjuvants (reviewed by van Rooijen and Su, 1989; Gregoriadis, 1990; Alving, 1991, 1992; Phillips, 1992). Although liposomes were originally developed as models of efferent mechanisms exhibited by the immune response, it has now become evident that antigens that are presented or reconstituted in liposomes can provide desirable properties that promote effective humoral and cellular immune responses in many vaccines.
